Lack of effect of dopaminergic antagonists in a rodent model of peritoneal sepsis

Cell Biology International

Volumn 31, Issue 9, 2007, Pages 1036-1041

  Machado, Roberta Albino ^a   Constantino, Larissa ^a   Martins, Márcio Rodrigo ^a   de Albuquerque, Isabella Martins ^a   Menna Barreto, Sérgio ^a   Streck, Emílio ^a   Quevedo, João ^a   Dal Pizzol, Felipe ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Clozapine; CLP; Dopamine; Haloperidol; Immunomodulator; Sepsis

Indexed keywords

BIOCHEMICAL MARKER; CEFTRIAXONE; CLINDAMYCIN; CLOZAPINE; CYTOKINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; MYELOPEROXIDASE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOPAMINERGIC SYSTEM; DRUG EFFECT; ENZYME ACTIVITY; IMMUNOMODULATION; INFLAMMATION; KIDNEY INJURY; LIVER INJURY; LUNG INJURY; MALE; MUSCLE INJURY; NONHUMAN; ORGAN INJURY; PANCREAS INJURY; PERITONITIS; RAT; SEPSIS; STRESS; SURVIVAL;

ANIMALS; BIOLOGICAL MARKERS; CLOZAPINE; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; HALOPERIDOL; INFLAMMATION; INTESTINAL PERFORATION; MALE; NEUTROPHIL INFILTRATION; PERITONEUM; RATS; RATS, WISTAR; SEPSIS;

ANIMALIA; RATTUS NORVEGICUS; RODENTIA;

EID: 34249334987     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2007.03.022     Document Type: Article

References (29)

1. Alkharfy K.M., Kellum J.A., and Matzke G.R. Unintended immunomodulation: Part II. Effects of pharmacological agents on cytokine activity. Shock 13 (2000) 346-360
2. Andrades M., Ritter C., Moreira J.C.F., and Dal-Pizzol F. Oxidative parameters differences during non-lethal and lethal sepsis development. J Surg Res 125 (2005) 68-72
3. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., and Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (2001) 1303-1310
4. Basu S., and Dasgupta P.S. Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 102 (2000) 113-124
5. Basu S., Dasgupta P.S., Lahiri T., and Roychowdhury J. Uptake and biodistribution of dopamine in bone marrow, spleen and lymph nodes of normal and tumor bearing mice. Life Sci 53 (1993) 415-424
6. Beishuizen A., and Thijs L.G. The immunoneuroendocrine axis in critical illness: beneficial adaptation or neuroendocrine exhaustion?. Curr Opin Crit Care 10 (2004) 461-467
7. Bergquist J., Tarkowski A., Ewing A., and Ekman R. Catecholaminergic suppression of immunocompetent cells. Immunol Today 19 (1998) 562-567
8. Hill A.G., Gonzalez J., Rounds J.D., and Wilmore D.W. Chronic central nervous system exposure to interleukin-1, but not interleukin-6, mediates catabolism in the rat. Surg Forum 45 (1994) 38-41
9. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. New Eng J Med 348 (2003) 138-150
10. Kleeb S.R., Rizzo M.S., Dagli M.L.Z., and Frussa-Filho R. Haloperidol increases spreading and nitric oxide production in macrophages from tumor-bearing mice: a possible mechanism for its antitumoral effect. Int J Immunopharmacol 21 (1999) 575-580
11. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
12. Lyson K., and McCann S.M. The effect of interleukin-6 on pituitary hormone release in vivo and in vitro. Neuroendocrinology 54 (1991) 262-266
13. Milbrandt E.B., Kersten A., Kong L., Weissfeld L.A., Clermont G., Mitchell F.P., et al. Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Crit Care Med 33 (2005) 226-229
14. Mohankumar P.S., Thyagarajan S., and Quadri S.K. Interleukin 1 stimulates the release of dopamine and dihydroxphenylacetic acid from the hypothalamus in-vivo. Life Sci 48 (1991) 925-930
15. Moots R.J., Al Saffar Z., Hutchinson D., Golding S., Young S., Baconet P., et al. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis 58 (1999) 585-587
16. Oberbeck R., Schmitz D., Wilsenack K., Schuler M., Pehle B., Schedlowski M., et al. Metoclopramide and cellular immune functions during polymicrobial sepsis. Eur Surg Res 36 (2004) 116-122
17. Polderman K.H., and Girbes A.R. Drug intervention trials in sepsis: divergent results. Lancet 363 (2004) 1721-1723
18. Qiu Y.H., Peng Y.P., Jiang J.M., and Wang J.J. Expression of tyrosine hydroxylase in lymphocytes and effect of endogenous catecholamines on lymphocyte function. Neuroimmunomodulation 11 (2004) 75-83
19. Reinke A., Martins M.R., Lima M.S., Moreira J.C., Dal-Pizzol F., and Quevedo J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 372 (2004) 157-160
20. Rettori V., Jurcovicova J., and McCann S.M. Central action of interleukin-1 in altering the release of TSH, growth hormone, and prolactin in the male rat. J Neurosci Res 18 (1987) 179-183
21. Ritter C., Andrades M., Reinke A., Menna-Barreto S., Moreira J.C.F., and Dal-Pizzol F. Treatment with N-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis. Crit Care Med 32 (2004) 342-349
22. Ritter C., Andrades M., Reinke A., Moreira J.C., and Dal-Pizzol F. Drug intervention trials in sepsis. Lancet 364 (2004) 498
23. Ritter C., da Cunha A.A., Echer I.C., Andrades M., Reinke A., Lucchiari N., et al. Effects of N-acetylcysteine plus deferoxamine in lipopolysaccharide-induced acute lung injury in the rat. Crit Care Med 34 (2006) 471-477
24. Roy S., Charboneau R., Cain K.J., Chapin R.B., and Barke R.A. The possible role of a central nervous system dopaminergic mechanism in hepatic c-fos protein expression following peritoneal sepsis. Arch Surg 130 (1995) 1209-1216
25. Schauenstein K., Rinner I., Felsner P., Liebmann P., Haas H.S., Wolfler A., et al. The dialogue between the brain and immune system involves not only the HPA-axis. Z Rheumatol 59 Suppl. 2 (2000) II/49-53
26. Schroder N., de Lima M.N., Quevedo J., Dal Pizzol F., and Roesler R. Impairing effects of chronic haloperidol and clozapine treatment on recognition memory: possible relation to oxidative stress. Schizophr Res 73 (2005) 377-378
27. Schweickert W., and Hall J.B. Agitation in the critically ill patient: a marker of health or a plea for treatment?. Crit Care Med 33 (2005) 263-265
28. Song C., Lin A., Kenis G., Bosmans E., and Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 42 (2000) 157-164
29. Zalcman S., Green-Johnson J.M., and Murray L. Cytokine specific central monoamine alterations induced by interleukin-1, -2, -6. Brain Res 643 (1994) 40-49